NasdaqGS:NUVLBiotechs
A Look At Nuvalent (NUVL) Valuation After Strong Multi‑Year Share Price Gains
Nuvalent stock reacts to oncology pipeline and recent returns
Nuvalent (NUVL), a clinical-stage cancer drug developer, has drawn attention after a run of strong recent returns, including about 55% over the past year and very large 3 year gains.
With a market value near US$7.0b and a last close of US$123.25, the stock now reflects expectations around its zero revenue profile, ongoing losses of US$450.074m, and multiple oncology programs in clinical trials.
See our latest analysis for...